PEPTIDEREPORT

Video claim watch

I Almost Died From a Fake Weight-Loss Injection

A first-person counterfeit-injection investigation gives the library a concrete product-integrity and illicit-market case.

Channel 4 News channel10:00 runtime24K views when checked

Published Oct 15, 2025. Metadata checked Jul 12, 2026.

Watch on YouTube

Transcript review

6 material claims logged

Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags5 source gaps

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

valuable investigative signal; medical causation and sample identity need lab/clinical documentation.

auto-caption available; no chapters.

Claim-by-claim audit

What the video says, and what needs checking

00:00:41
High-risk safety claimHigh-risk quality claim

reports a purchaser became severely ill after a TikTok-sourced injection, with vomiting and visual symptoms.

Review topic: counterfeit adverse event.

Checked against: Primary-source record still needed

clinical records/toxicology if available; anecdote does not identify ingredient.

00:01:42
High-risk regulatory claimHigh-risk commercial claim

documents sellers on Facebook/Instagram/WhatsApp offering products without screening and encouraging escalation.

Review topic: platform sales / provider absence.

Checked against: Primary-source record still needed

preserved messages and platform policies.

00:05:21
High-risk quality claim

shows convincing packaging falsely naming another manufacturer while Lilly is the developer.

Review topic: counterfeit/provenance.

Checked against: Primary-source record still needed

manufacturer confirmation and lab analysis.

00:05:57
High-risk quality claimHigh-risk commercial claim

makes country-of-origin and very-low-cost claims for bulk supply.

Review topic: supply chain.

Checked against: Primary-source record still needed

customs/law-enforcement records; do not repeat as established without documentation.

00:09:36
Regulatory context

says TikTok/Meta removed content and banned relevant searches after the investigation.

Review topic: platform enforcement.

Checked against: Primary-source record still needed

platform statements and post-removal checks.

Connected research

Compounds discussed

Retatrutide Retatrutide has produced large weight reductions in randomized Phase 2 and Phase 3 trials, but it remains unapproved. Long-term outcomes, direct comparisons, rare risks, durability, and final regulatory decisions remain unresolved.

Source check

Records used in this claim audit

TRIUMPH-1: retatrutide in participants with obesity or overweight

ClinicalTrials.gov · Primary regulatory · Jul 3, 2023 · accessed Jul 12, 2026

Completed Phase 3 master protocol NCT05929066. The registry identifies TRIUMPH-1 as a randomized, double-blind, placebo-controlled study in adults without type 2 diabetes who have obesity or overweight.

12 linked pagesOpen original · clinicaltrials-retatrutide-triumph1